Ixekizumab

RED^1,2,3 : NICE TA 442 - Ixekizumab for treating moderate to severe plaque psoriasis. (Decision date - May 2017)

RED^1,2,3: NICE TA537 - ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs.(Decision date - September 2018)

RED1,2,3: NICE TA718 - Ixekizumab for treating active axial spondylitis. (Decision date - August 2021)

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)